Accounts Receivable, after Allowance for Credit Loss, Current of Universe Pharmaceuticals INC from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Universe Pharmaceuticals INC quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Universe Pharmaceuticals INC Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2025 was $13,008,117, a 0.79% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Universe Pharmaceuticals INC Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $13,008,117 +$102,296 +0.79% 30 Sep 2025 20-F 29 Jan 2026 2025 FY
Q3 2024 $12,905,821 +$1,890,913 +17% 30 Sep 2024 20-F 29 Jan 2026 2025 FY
Q1 2024 $14,384,228 -$3,135,040 -18% 31 Mar 2024 6-K 20 Sep 2024 2024 Q2
Q3 2023 $11,014,908 -$4,168,982 -27% 30 Sep 2023 20-F 29 Apr 2025 2024 FY
Q1 2023 $17,519,268 -$1,297,138 -6.9% 31 Mar 2023 6-K 31 Aug 2023 2023 Q2
Q3 2022 $15,183,890 -$389,852 -2.5% 30 Sep 2022 20-F 30 Jan 2024 2023 FY
Q1 2022 $18,816,406 31 Mar 2022 6-K 16 Aug 2022
Q3 2021 $15,573,742 +$4,701,964 +43% 30 Sep 2021 20-F 10 Feb 2023 2022 FY
Q3 2020 $10,871,778 30 Sep 2020 20-F 31 Jan 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.